Shi, Y., He, X., Yang, S., Ai, B., Zhang, C., Huang, D., et al. (2007). Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. Chemotherapy, 53(1), 44-50.
To compare the efficacy and safety of two different 5-HT3 receptor antagonists
Patients were randomized to one of two groups. In the first group, patients received ramosetron for prevention of chemotherapy-induced nausea and vomiting (CINV) in cycle 1 of highly emetogenic chemotherapy (HEC) and then ondansetron in cycle 2. Patients in group 2 received ondansetron first, followed by ramosetron.
The study consisted of 50 patients.
The study was conducted in China.
This was a prospective, randomized, crossover trial.
Nausea, emesis, and loss of appetite were assessed, but the authors did not describe how this data was collected or by whom.
No significance was reported for any measure between groups at any time point.
No significant differences were reported between the two groups on any measure at any time point